Prodigiosin analogs and methods of use

A compound of Formula XIV:

• wherein:
• R1 and R2 are, independently, selected from the group consisting of H, OH, halogen, —C1-6alkyl, —C1-6 fluoroalkyl, —CN, —NO2, —OR7, —SR7, —S(═O)R7, —S(═O)R7, —NHS(═O)2 R7, —C(═O)R7, —OC(═O)R7, —CO2R7, —OCO2 R7, —CH(R7)2, —N(R7)2, —C(═O)N(R7)2, —NHC(═O)NHR7, —NHC(═O)R7, —NHC(═O)OR7, —C(OH)(R7)2, and —C(NH2)(R7)2;
• each R7 is, independently, H, halogen, or C1-C6 alkyl, wherein the alkyl group is optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halogen, OH, CN, and NO2;
• R3 is an optionally substituted aryl or an optionally substituted heteroaryl;
• R4, R5, and R6 are, independently, OH, —C1-10 alkyl, —OC1-10-alkyl, or —SC1-10alkyl, wherein each alkyl group is, independently, optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halogen, OH, CN, and NO2;
• and
• n is an integer from 0 to 5;
• or a tautomer or solvate thereof, or a pharmaceutically acceptable salt thereof;
• provided that:
• if n is 0, then R3 is not an optionally substituted pyrrolyl;
• and
• if n is 2, then the compound is not